Table 1.
Characteristics of the study population by CKD stage
| Characteristic | Overall | Stage 2 (GFR≥60 ml/min per 1.73 m2) | Stage 3a (GFR=45–59 ml/min per 1.73 m2) | Stage 3b (GFR=30–44 ml/min per 1.73 m2) | Stage 4 (GFR=15–29 ml/min per 1.73 m2) |
|---|---|---|---|---|---|
| Number | 464 | 103a | 127 | 145 | 89 |
| Age, yr | 11.7 [8.4, 15.1] | 11.2 [7.0, 15.3] | 11.5 [8.1, 15.0] | 11.4 [8.6, 15.1] | 13.6 [9.6, 15.2] |
| Girls | 39 (181) | 37 (38) | 41 (52) | 36 (52) | 44 (39) |
| Race | |||||
| Caucasian | 70 (323) | 55 (57) | 71 (90) | 77 (112) | 72 (64) |
| African American | 20 (93) | 35 (36) | 19 (24) | 14 (20) | 15 (13) |
| Multiracial or other | 10 (48) | 10 (10) | 10 (13) | 9 (13) | 13 (12) |
| Hispanic ethnicity | 14 (61) | 10 (9) | 15 (18) | 14 (21) | 14 (13) |
| Primary CKD diagnosis | |||||
| Glomerular | 20 (94) | 27 (28) | 18 (23) | 17 (24) | 21 (19) |
| Obstruction/reflux | 37 (174) | 40 (41) | 43 (54) | 32 (46) | 37 (33) |
| Hypoplasia/dysplasia | 18 (82) | 13 (13) | 15 (919) | 22 (32) | 20 (18) |
| Other nonglomerular | 20 (93) | 18 (19) | 19 (24) | 26 (38) | 14 (12) |
| Cystic disease | 5 (21) | 2 (2) | 5 (7) | 3 (5) | 8 (7) |
| Medication use | |||||
| Phosphate binders | 21 (98) | 6 (6) | 11 (14) | 23 (34) | 49 (44) |
| Nutritional vitamin D | 5 (22) | 3 (3) | 4 (5) | 7 (10) | 5 (4) |
| Active vitamin D | 38 (178) | 8 (8) | 29 (37) | 49 (71) | 70 (62) |
Data are medians [25th, 75th percentiles] or percentage (number).
a
Includes 11 participants with CKD stage 1 (GFR=90–109 ml/min per 1.73 m2).